ArticleNature metabolism2021
SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation.
Open access · greenAbstract readLetter
In one paragraph
Article in Nature metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Metabolic regulation and immunosuppressive functions of lipid-associated macrophages in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Pooled it
- Coenzyme A activates TLR4 and enhances alternative macrophage activation in line with MyD88 agonism.EMBO reports · 2026Article
- Metabolic Targeting of SREBP1 Reprograms the Obesity-Driven Ascites Immune Microenvironment and Enhances Chemotherapy Response in Obesity-Associated Ovarian Cancer.bioRxiv : the preprint server for biology · 2026Article
- Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity.Nature cancer · 2026Article
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- Every-Other-Day Fasting Prehabilitation Attenuates Secondary Injury Following Spinal Cord Injury and Is Associated with Stage-Dependent SREBP1-Related Metabolic-Immune Remodeling.Molecular neurobiology · 2026Article
- ACOT1-specific expression modulates metabolic reprogramming in diabetic cardiomyopathy: The role of SREBP1c lactylation in CD36-mediated lipotoxicity.American heart journal plus : cardiology research and practice · 2026Article
- Metabolic Reprogramming-Driven Cardiovascular Immune Damage: From Glyco-Lipotoxicity and Epigenetic Memory to Multidimensional Cross-Organ Communication Networks.International journal of molecular sciences · 2026Review
- Integrated analysis of insulin resistance reveals metabolic remodeling following diet switch-triggered calorie reduction.Science advances · 2026Article
- Impaired glucose tolerance and mild diabetes induce β-cell dysfunction in mice.Nature communications · 2026Article
- SREBP1-activated lipid metabolism drives ferroptosis and progression of clear cell renal cell carcinoma.Science China. Life sciences · 2026Article
- Macrophage Metabolic Reprogramming-Related Osteoimmunity in Osteoporosis.Calcified tissue international · 2026Review
- Hic-5 promotes the progression of nonalcoholic steatohepatitis by regulating hepatocellular fatty acid metabolism through the PTEN/PGE2/EP4 axis.Molecular biomedicine · 2026Article
- Metabolic Dysregulation in Laminopathies: Implications for Heart Failure and Cardiac Health.Current heart failure reports · 2026Review
- Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk.Lipids in health and disease · 2026Review
- GIPC2 regulation of the PKM2/SREBP1 signaling axis controls adipogenic differentiation of mesenchymal stem cells.Cell death & disease · 2026Article
- Lipid metabolism-MAFLD crosstalk: mechanisms and therapy.Frontiers in endocrinology · 2026Review
- Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.Frontiers in pharmacology · 2026Review
- The role of macrophages in radiation-induced lung injury: from pathological mechanisms to therapeutic targets.Frontiers in immunology · 2026Review
- The impact of macrophage metabolism on idiopathic pulmonary fibrosis development and treatment prospectives.Frontiers in immunology · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Guillaume BidaultUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK. gb483@medschl.cam.ac.uk.ORCID http://orcid.org/0000-0002-8396-9962
Samuel VirtueUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-9545-5432
Kasparas PetkeviciusUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0003-2295-6065
Helen E JolinMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.
Aurélien DugourdInstitute for Computational Biomedicine, Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, BioQuant, Heidelberg, Germany.
Anne-Claire GuénantinUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.
Jennifer LeggatUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-1040-6827
Betania Mahler-AraujoUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.
Brian Y H LamUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.
Marcella K MaUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-2228-7466
Martin DaleUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.
Stefania CarobbioUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK.
Arthur KaserCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), and Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, UK.
Padraic G FallonSchool of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Julio Saez-RodriguezInstitute for Computational Biomedicine, Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, BioQuant, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8552-8976
Andrew N J McKenzieMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0001-9757-2512
Antonio Vidal-PuigUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, MDU MRC, Addenbrooke's Hospital, Cambridge, UK. ajv22@medschl.cam.ac.uk.ORCID http://orcid.org/0000-0003-4220-9577
University of Cambridge · GBHeidelberg University · DEMRC Laboratory of Molecular Biology · GBTrinity College Dublin · IE
Funding
British Heart Foundation RG/12/13/29853British Heart Foundation RG/18/7/33636Medical Research Council G0400192Medical Research Council G0802051Medical Research Council MC_G0802535Medical Research Council MC_U105178805Medical Research Council MC_UU_00014/2Medical Research Council MC_UU_12012/2Medical Research Council MC_UU_12012/5Medical Research Council MRC_MC_UU_12012/5Medical Research Council U105178805Wellcome Trust 100574Wellcome Trust 100963Wellcome Trust 106260Wellcome Trust (Wellcome) 100574/Z/12/ZWellcome Trust (Wellcome) 100963/Z/13/ZWellcome Trust (Wellcome) 106260/Z/14/Z
Abstract
Macrophages exhibit a spectrum of activation states ranging from classical to alternative activation
Indexed as
AnimalsAntioxidantsDexamethasoneFatty AcidsHumansInterleukin-4LipopolysaccharidesMacrophage ActivationMacrophagesMiceMice, KnockoutNippostrongylusRAW 264.7 CellsSequence Analysis, RNASterol Regulatory Element Binding Protein 1Strongylida InfectionsAntioxidantsDexamethasoneFatty AcidsInterleukin-4LipopolysaccharidesSREBF1 protein, humanSterol Regulatory Element Binding Protein 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.